Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.56 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1341778 | 0.98 | SMN1; SMN2 (0.55) | NAAAEPHX1SMN1; SMN2HSD17B10HDAC8 | |
| SCHEMBL1340685 | 0.94 | SMN1; SMN2 (0.50) | NAAAEPHX1SMN1; SMN2HSD17B10HDAC8 | |
| SCHEMBL1342010 | 0.90 | — | — | |
| SCHEMBL6445858 | 0.81 | NAAA (0.57) | NAAAEPHX1SMN1; SMN2HSD17B10HDAC8 | |
| SCHEMBL30832082 | 0.81 | KMT2A (0.58) | NAAAEPHX1SMN1; SMN2HSD17B10KMT2A | |
| SCHEMBL24116980 | 0.81 | KMT2A (0.58) | NAAAEPHX1SMN1; SMN2HSD17B10KMT2A | |
| SCHEMBL4257123 | 0.81 | KDM4E (0.40) | NAAAEPHX1SMN1; SMN2HSD17B10KMT2A | |
| SCHEMBL1674736 | 0.81 | KMT2A (0.58) | NAAAEPHX1SMN1; SMN2HSD17B10KMT2A | |
| SCHEMBL17592152 | 0.81 | NAAA (0.57) | NAAAEPHX1SMN1; SMN2HSD17B10HDAC8 | |
| SCHEMBL2535622 | 0.81 | GNAI3 (0.57) | NAAAEPHX1SMN1; SMN2HSD17B10KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10016448-B2 | Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity | MERCK PATENT GMBH (DE) | 2018-07-10 | — | — | US | claimed |
| US-20170136048-A1 | COMPOSITIONS AND METHODS FOR THE PRODUCTION OF PYRIMIDINE AND PYRIDINE COMPOUNDS WITH BTK INHIBITORY ACTIVITY | MERCK PATENT GMBH (DE) | 2017-05-18 | — | — | US | claimed |
| US-20140162983-A1 | Compositions and Methods for the Production of Pyrimidine and Pyridine Compounds with BTK Inhibitory Activity | MERCK PATENT GMBH (DE) | 2014-06-12 | — | — | US | claimed |
| US-6991890-B2 | Negative photoresist composition involving non-crosslinking chemistry | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2006-01-31 | — | — | US | claimed |
| US-20050175928-A1 | Negative photoresist composition involving non-crosslinking chemistry | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2005-08-11 | — | — | US | claimed |
| US-20250161304-A1 | Methods for Treating Cancer Using Pyrimidine and Pyridine Compounds with BTK Inhibitory Activity | MERCK PATENT GMBH (DE) | 2025-05-22 | — | — | US | disclosed |
| US-11491153-B2 | Methods for treating cancer using pyrimidine and pyridine compounds with BTK inhibitory activity | MERCK PATENT GMBH (DE) | 2022-11-08 | — | — | US | disclosed |
| US-20200316068-A1 | Methods for Treating MS Using Pyrimidine and Pyridine Compounds with BTK Inhibitory Activity | MERCK PATENT GMBH (DE) | 2020-10-08 | — | — | US | disclosed |
| US-10716788-B2 | Methods for treating MS using pyrimidine and pyridine compounds with BTK inhibitory activity | MERCK PATENT GMBH (DE) | 2020-07-21 | — | — | US | disclosed |
| US-20200206224-A1 | Methods for Treating Cancer Using Pyrimidine and Pyridine Compounds with BTK Inhibitory Activity | MERCK PATENT GMBH (DE) | 2020-07-02 | — | — | US | disclosed |
| CN-104603105-B | It is used as the formamide or nitrogenous 5 circle heterocycles of sulfonamide substitutions of orphan nuclear receptor ROR gamma modulators | 菲尼克斯药品股份公司 | 2017-09-08 | — | — | CN | disclosed |
| US-20170136018-A1 | Methods for Treating MS Using Pyrimidine and Pyridine Compounds with BTK Inhibitory Activity | MERCK PATENT GMBH (DE) | 2017-05-18 | — | — | US | disclosed |
| US-20050176792-A1 | Ketone substituted benzimidazole compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-08-11 | — | — | US | disclosed |
| US-20050175928-A1 | Negative photoresist composition involving non-crosslinking chemistry | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2005-08-11 | — | — | US | disclosed |
| WO-2005070420-A1 | 1H-BENZIMIDAZOL-2-YL-BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ITK INHIBITORS (INTERLEUKIN-2-INDUCIBLE T CELL KINASE) FOR THE TREATMENT OF INFLAMMATION, IMMUNOLOGICAL AND ALLERGIC DISORDERS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-08-04 | — | — | WO | disclosed |
| WO-2005058228-A2 | COMT INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-30 | — | — | WO | disclosed |
| US-20050137162-A1 | New COMT inhibitors for the treatment of depression and impaired cognition | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-23 | — | — | US | disclosed |
| EP-1531815-A1 | GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2005-05-25 | — | — | EP | disclosed |
| US-20040122235-A1 | Aryl carbonyl derivatives as therapeutic agents | VTV THERAPEUTICS LLC | 2004-06-24 | — | — | US | disclosed |
| WO-2004002481-A1 | ARYL CARBONYL DERIVATIVES AS THERAPEUTIC AGENTS | NOVO NORDISK A/S (DK) | 2004-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176792-A1 | Ketone substituted benzimidazole compounds | ITK, BLK, BCKDK | NAAA 3503/4885EPHX1 1454/4885SMN1; SMN2 4238/4885 |
| US-20200316068-A1 | Methods for Treating MS Using Pyrimidine and Pyridine Compounds with BTK Inhibitory Activity | BTK, LCK, SYK | NAAA 2004/4885EPHX1 1212/4885SMN1; SMN2 2635/4885 |
| US-10016448-B2 | Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity | BTK, SYK, LCK | NAAA 3922/4885EPHX1 1576/4885SMN1; SMN2 4722/4885 |
| US-10716788-B2 | Methods for treating MS using pyrimidine and pyridine compounds with BTK inhibitory activity | BTK, LCK, SYK | NAAA 2004/4885EPHX1 1212/4885SMN1; SMN2 2635/4885 |
| US-20200206224-A1 | Methods for Treating Cancer Using Pyrimidine and Pyridine Compounds with BTK Inhibitory Activity | BTK, SYK, LCK | NAAA 2817/4885EPHX1 1287/4885SMN1; SMN2 4593/4885 |
| US-20250161304-A1 | Methods for Treating Cancer Using Pyrimidine and Pyridine Compounds with BTK Inhibitory Activity | BTK, SYK, LCK | NAAA 2817/4885EPHX1 1287/4885SMN1; SMN2 4593/4885 |
| US-20140162983-A1 | Compositions and Methods for the Production of Pyrimidine and Pyridine Compounds with BTK Inhibitory Activity | BTK, SYK, LCK | NAAA 3922/4885EPHX1 1576/4885SMN1; SMN2 4722/4885 |
| US-11491153-B2 | Methods for treating cancer using pyrimidine and pyridine compounds with BTK inhibitory activity | BTK, SYK, LCK | NAAA 2817/4885EPHX1 1287/4885SMN1; SMN2 4593/4885 |
| US-20170136048-A1 | COMPOSITIONS AND METHODS FOR THE PRODUCTION OF PYRIMIDINE AND PYRIDINE COMPOUNDS WITH BTK INHIBITORY ACTIVITY | BTK, SYK, LCK | NAAA 3922/4885EPHX1 1576/4885SMN1; SMN2 4722/4885 |
| US-20170136018-A1 | Methods for Treating MS Using Pyrimidine and Pyridine Compounds with BTK Inhibitory Activity | BTK, LCK, SYK | NAAA 2004/4885EPHX1 1212/4885SMN1; SMN2 2635/4885 |
| US-20040122235-A1 | Aryl carbonyl derivatives as therapeutic agents | GCK, GCKR, PDK2 | NAAA 2320/4885EPHX1 3518/4885SMN1; SMN2 2958/4885 |
| US-20050137162-A1 | New COMT inhibitors for the treatment of depression and impaired cognition | COMT, MAOB, TPH1 | NAAA 2762/4885EPHX1 118/4885SMN1; SMN2 1274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.